CureSearch Research Programs: information for Applicants
In order to ensure that CureSearch funds the best science with the greatest potential to reach pediatric cancer patients in an accelerated time-frame, CureSearch employs a rigorous review process that engages members throughout the drug development ecosystem. Input of scientists, oncologists, and industry experts enables CureSearch to support projects that are positioned to succeed.
CureSearch application submissions and reviews follow a two-stage process. Applicants first must submit a “Letter of Intent” (LOI). LOIs are administratively reviewed by CureSearch Scientific Staff and then reviewed by the CureSearch Scientific Review Committee (SRC). Top scoring LOIs are invited to submit full proposals, which elaborate on the projects initially outlined in the LOI.
CureSearch Grant Cycle Timeline
Funding Opportunity Announcement
The application window to submit Letters of Intent (LOIs) will open June 6, 2022. CureSearch will fund high potential projects that address areas of unmet need in pediatric cancer, leading to the development of better, less-toxic children’s cancer treatments.
| TIMELINE | DATES |
| Request for Applications Opens | June 6, 2022 |
| Letter of Intent Deadline | July 18, 2022 |
| LOI Notification/Full Applications Invited | August 29, 2022 |
| Full Applications Due | October 11, 2022 |
| Earliest Award Notification* | January 1, 2023 |
| Program | Opportunity Summary | Submission Site |
| Young Investigator | An opportunity for funding up to $75,000 per year for up to three years. Provides seed support for bright researchers, early in their careers, pursuing exciting and novel research in pediatric oncology. | LOI application window opens June 6, 2022 on ProposalCentral |
| Catapult Award | An opportunity for funding in the range of $500,000-$2.5 million. CureSearch’s Catapult Award program aims to accelerate the development of novel, innovative, less-toxic treatments for children with cancer. The goal of the Catapult Award is to overcome barriers to pediatric cancer drug development by providing meaningful funding in order to advance the development of promising oncology research out of the lab and into clinical trials. | LOI application window opens June 6, 2022 on ProposalCentral |
Click here to add yourself to our mailing list and be the first to know about new RFAs.
Please email Caitlyn Barrett, PhD, Senior Director of Research and Programs, with any questions or comments.